Prolato Clinical Research Center

Houston, Texas 77054-2853

14 studies enrolling now · 41 studies all time

What they study most

AChR Myasthenia Gravis, Active Refractory Rheumatoid Arthritis, Alport Syndrome, Arthritis, Rheumatoid, COVID-19, Cardiovascular Risk, Chronic Kidney Disease, Chronic Kidney Diseases, Diabetes Complications, Diabetes Mellitus, Diabetic Kidney Disease, Diabetic Nephropathies

Studies at this site

• A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases — Recruiting now
• Study of WAL0921 in Patients With Glomerular Kidney Diseases — Recruiting now
• A Study of Dotinurad Versus Allopurinol in Tophaceous Gout — Recruiting now
• A Study of Dotinurad Versus Allopurinol in Participants With Gout — Recruiting now
• Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V — Recruiting now
• Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN — Recruiting now
• Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis — Recruiting now
• Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN — Recruiting now
• A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis — Recruiting now
• A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression — Recruiting now
• R-2487 in Patients With Rheumatoid Arthritis — Recruiting now
• Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease — Recruiting now
• Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy — Recruiting now
• An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus — Enrolling by invitation
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation — Completed
• Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) — Running, not enrolling
• A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old — Completed
• A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. — Running, not enrolling
• Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) — Completed
• Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome — Running, not enrolling
• Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN) — Completed
• Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis — Running, not enrolling
• Atrasentan in Patients With Proteinuric Glomerular Diseases — Running, not enrolling
• Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus — Running, not enrolling
• A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome — Stopped early
• Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities — Running, not enrolling
• Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS — Stopped early
• A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity — Running, not enrolling
• Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients — Completed
• Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis — Completed
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza — Completed
• A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older — Completed
• A Study of Imvotamab in Severe Systemic Lupus Erythematosus — Stopped early
• A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria — Withdrawn before enrolling
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza — Completed
• An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases — Stopped early
• A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease — Stopped early
• Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease — Status unconfirmed